Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity.


Journal

The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355

Informations de publication

Date de publication:
12 2021
Historique:
received: 20 01 2021
revised: 29 07 2021
accepted: 02 08 2021
pubmed: 18 10 2021
medline: 15 3 2022
entrez: 17 10 2021
Statut: ppublish

Résumé

Universal testing and treatment (UTT) for all people living with HIV has only been assessed under experimental conditions in cluster-randomised trials. The public health effectiveness of UTT policies on the HIV care cascade under real-world conditions is not known. We assessed the real-world effectiveness of universal HIV treatment policies that were implemented in Zambia on Jan 1, 2017. We used data from Zambia's routine electronic health record system to analyse antiretroviral therapy (ART)-naive adults who newly enrolled in HIV care up to 1 year before and after the implementation of universal treatment (ie, Jan 1, 2016, to Jan 1, 2018) at 117 clinics supported by the Centre for Infectious Disease Research in Zambia. We used a regression discontinuity design to estimate the effects of implementing UTT on same-day ART initiation, ART initiation within 1 month, and retention on ART at 12 months (defined as clinic attendance 9-15 months after enrolment and at least 6 months on ART), under the assumption that patients presenting immediately before and after UTT implementation were balanced on both measured and unmeasured characteristics. We did an instrumental variable analysis to estimate the effect of same-day ART initiation under routine conditions on 12-month retention on ART. 65 673 newly enrolled patients with HIV (40 858 [62·2%] female, median age 32 years [IQR 26-39], median CD4 count 287 cells per μL [IQR 147-466]) were eligible for inclusion in the analyses; 31 145 enrolled before implementation of UTT, and 34 528 enrolled after UTT. Implementation of universal treatment increased same-day ART initiation from 41·7% to 74·8% (risk difference [RD] 33·1%, 95% CI 30·5-35·7), ART initiation by 1 month from 69·6% to 87·0% (RD 17·4%, 15·5-19·3), and 12-month retention on ART from 56·2% to 63·3% (RD 7·1%, 4·3-9·9). ART initiation rates became more uniform across patient subgroups after implementation of universal treatment, but heterogeneity in 12-month retention on ART between subgroups was unchanged. Instrumental variable analyses indicated that same-day ART initiation in routine settings led to a 15·8% increase (95% CI 12·1-19·5) in 12-month retention on ART. UTT policies implemented in Zambia increased the rapidity and uptake of ART, as well as retention on ART at 12 months, although overall retention on ART remained suboptimal. UTT policies reduced disparities in treatment initiation, but not 12-month retention on ART. Natural experiments reveal both the anticipated and unanticipated effects of real-world implementation and indicate the need for new strategies leveraging the short-term effects of UTT to cultivate long-term treatment success. National Institutes of Health.

Sections du résumé

BACKGROUND
Universal testing and treatment (UTT) for all people living with HIV has only been assessed under experimental conditions in cluster-randomised trials. The public health effectiveness of UTT policies on the HIV care cascade under real-world conditions is not known. We assessed the real-world effectiveness of universal HIV treatment policies that were implemented in Zambia on Jan 1, 2017.
METHODS
We used data from Zambia's routine electronic health record system to analyse antiretroviral therapy (ART)-naive adults who newly enrolled in HIV care up to 1 year before and after the implementation of universal treatment (ie, Jan 1, 2016, to Jan 1, 2018) at 117 clinics supported by the Centre for Infectious Disease Research in Zambia. We used a regression discontinuity design to estimate the effects of implementing UTT on same-day ART initiation, ART initiation within 1 month, and retention on ART at 12 months (defined as clinic attendance 9-15 months after enrolment and at least 6 months on ART), under the assumption that patients presenting immediately before and after UTT implementation were balanced on both measured and unmeasured characteristics. We did an instrumental variable analysis to estimate the effect of same-day ART initiation under routine conditions on 12-month retention on ART.
FINDINGS
65 673 newly enrolled patients with HIV (40 858 [62·2%] female, median age 32 years [IQR 26-39], median CD4 count 287 cells per μL [IQR 147-466]) were eligible for inclusion in the analyses; 31 145 enrolled before implementation of UTT, and 34 528 enrolled after UTT. Implementation of universal treatment increased same-day ART initiation from 41·7% to 74·8% (risk difference [RD] 33·1%, 95% CI 30·5-35·7), ART initiation by 1 month from 69·6% to 87·0% (RD 17·4%, 15·5-19·3), and 12-month retention on ART from 56·2% to 63·3% (RD 7·1%, 4·3-9·9). ART initiation rates became more uniform across patient subgroups after implementation of universal treatment, but heterogeneity in 12-month retention on ART between subgroups was unchanged. Instrumental variable analyses indicated that same-day ART initiation in routine settings led to a 15·8% increase (95% CI 12·1-19·5) in 12-month retention on ART.
INTERPRETATION
UTT policies implemented in Zambia increased the rapidity and uptake of ART, as well as retention on ART at 12 months, although overall retention on ART remained suboptimal. UTT policies reduced disparities in treatment initiation, but not 12-month retention on ART. Natural experiments reveal both the anticipated and unanticipated effects of real-world implementation and indicate the need for new strategies leveraging the short-term effects of UTT to cultivate long-term treatment success.
FUNDING
National Institutes of Health.

Identifiants

pubmed: 34656208
pii: S2352-3018(21)00186-7
doi: 10.1016/S2352-3018(21)00186-7
pmc: PMC8639712
mid: NIHMS1750943
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e755-e765

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI134413
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002346
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests AMo and EHG report funding from the US National Institutes of Health (NIH) during the conduct of this study. IS, MWM, TS, MEH, and CB-M report support from the US President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC during the conduct of this study. IS, CB-M, IE-W, CBH, CB-M, and EHG report grants from the Bill & Melinda Gates Foundation outside the submitted work. EHG reports educational grants from ViiV Healthcare outside the submitted work. CBH reports consulting for the Bill & Melinda Gates Foundation and support for participating in an expert panel from Merck outside the submitted work. All other authors declare no competing interests.

Références

Lancet HIV. 2016 Dec;3(12):e554-e555
pubmed: 27771232
J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):62-72
pubmed: 33105396
PLoS Med. 2016 Aug 09;13(8):e1002106
pubmed: 27505444
Clin Infect Dis. 2020 Dec 3;71(9):2497-2499
pubmed: 32373932
J Int AIDS Soc. 2020 Feb;23(2):e25455
pubmed: 32091179
Epidemiology. 2013 May;24(3):370-4
pubmed: 23549180
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29314658
Patient. 2021 Mar;14(2):175-186
pubmed: 32909218
Lancet HIV. 2016 Nov;3(11):e539-e548
pubmed: 27658873
PLoS One. 2020 Oct 19;15(10):e0240865
pubmed: 33075094
PLoS Med. 2019 Jun 10;16(6):e1002822
pubmed: 31181056
PLoS One. 2020 Jan 14;15(1):e0227572
pubmed: 31935240
J Clin Epidemiol. 2015 Feb;68(2):122-33
pubmed: 25579639
Curr HIV/AIDS Rep. 2020 Oct;17(5):458-466
pubmed: 32844274
J Int AIDS Soc. 2020 Jun;23(6):e25529
pubmed: 32510186
PLoS Med. 2017 Jul 25;14(7):e1002357
pubmed: 28742880
Clin Infect Dis. 2020 Dec 17;71(10):2608-2614
pubmed: 31781759
PLoS Med. 2018 Jun 5;15(6):e1002574
pubmed: 29870531
Lancet HIV. 2020 Aug;7(8):e545-e553
pubmed: 32763218
Epidemiology. 2006 Jul;17(4):360-72
pubmed: 16755261
J Int AIDS Soc. 2020 Mar;23(3):e25458
pubmed: 32128964
J Clin Epidemiol. 2017 Sep;89:53-66
pubmed: 28365306
J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):153-161
pubmed: 32084052
J Int AIDS Soc. 2019 Apr;22(4):e25279
pubmed: 30993854
J Int AIDS Soc. 2020 Sep;23(9):e25610
pubmed: 32949103
PLoS Med. 2019 May 31;16(5):e1002811
pubmed: 31150380
PLoS Med. 2020 Aug 27;17(8):e1003226
pubmed: 32853271
PLoS Med. 2017 Jul 25;14(7):e1002358
pubmed: 28742819
PLoS Med. 2019 Dec 31;16(12):e1003020
pubmed: 31891581
PLoS One. 2020 Nov 4;15(11):e0241477
pubmed: 33147250

Auteurs

Aaloke Mody (A)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA. Electronic address: aaloke.mody@wustl.edu.

Izukanji Sikazwe (I)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Angella Sandra Namwase (AS)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA.

Mwanza Wa Mwanza (M)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Theodora Savory (T)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Annie Mwila (A)

Center for Disease Control, Lusaka, Zambia.

Lloyd Mulenga (L)

Zambian Ministry of Health, Lusaka, Zambia.

Michael E Herce (ME)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.

Keith Mweebo (K)

Center for Disease Control, Lusaka, Zambia.

Paul Somwe (P)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Ingrid Eshun-Wilson (I)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA.

Kombatende Sikombe (K)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; Department of Public Health Environments and Society, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.

Laura K Beres (LK)

Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.

Jake Pry (J)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Charles B Holmes (CB)

Department of Medicine, Georgetown University, Washington, DC, USA.

Carolyn Bolton-Moore (C)

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; Division of Infectious Diseases, University of Alabama, Birmingham, AL, USA.

Elvin H Geng (EH)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH